Navigation Links
Eularis Releases Comprehensive Report on Effective and Measurable Pharmaceutical eMarketing Using Social Media
Date:5/18/2009

NEW YORK and LONDON, May 18 /PRNewswire/ -- Eularis is announcing the release of an update to its report "Pharmaceutical eMarketing: Building Brands, Relationships & Business Through Web 2.0 and Beyond." The comprehensive report has been created to demystify the world of eMarketing and Social Media to provide Pharmaceutical marketers with a competitive edge and the latest information on how to use these emerging tools.

"As market growth slows, the bottom line return for brands is under increased scrutiny, and every marketing dollar must count," said the author of the report, Dr. Andree K. Bates, President of Eularis. "The emerging social media tools are inexpensive to implement, highly effective for gaining prescriptions when implemented as part of a cohesive strategy, and measurement of the financial impact of using them, using analytics, is certainly possible for justification to management."

Many pharma companies still flounder when it comes to justifying online marketing and can still be stumped by how to use the plethora of emerging social media tools now available. This challenge can be troublesome enough to prompt some companies & marketers to sit it out completely, or to half-heartedly engage in some online activities - like blogs, YouTube, Twitter and Facebook - without a real plan. New initiatives are started & neglected, or focused entirely on the wrong things. As a result, companies miss out and waste time, money and opportunity.

However, this report shows how an eMarketing campaign that is built on strategy & a deep knowledge of an audience can be powerful. The report examines specific tools in the social media age, observing how patients, physicians and companies use blogs, social networking, Twitter, YouTube and other new media tools... and develop best practices for their use. Finally, we tie it all together, examining key case studies of eMarketing campaigns, giving instructions on first steps for your own campaign, and taking a close look at measurement.

eMarketing can be a challenge. However, with some company initiative, firm goals and the insider knowledge provided by this report, marketers can also find eMarketing to be an empowering opportunity for their brands.

To purchase this report, please visit: http://www.epharmaroi.com/

About Eularis

Eularis provides sophisticated Pharmaceutical analytics that provide data-driven insight into the financial impact of corporate and marketing decisions. Unlike traditional analytics approaches, which are lengthy and whose reliance on historical or analogue data reduces their accuracy, Eularis' proprietary 94.8 Analytics Process is based on the current market situation. This proven approach helps Pharmaceutical marketing teams to quickly plan, measure, validate and optimize their sales and marketing performance, knowing where to focus, and how to budget, for maximum financial return. Co-headquartered in London and New York City, the company has developed significant experience in the global Pharmaceutical market through client engagements with AstraZeneca, GlaxoSmithKline, Merck, Pfizer and many others. For more information, visit www.eularis.com.

This release was issued on behalf of the above organization by Send2Press(R), a unit of Neotrope(R). http://www.Send2Press.com


'/>"/>
SOURCE Eularis
Copyright©2009 PR Newswire.
All rights reserved

Related medicine news :

1. Eularis Announces New Corporate Name and Expanded Product Offerings
2. Eularis Releases Update of Its Comprehensive Report on Maximizing the Bottom Line in Pharmaceutical Marketing
3. MEDIA ALERT: Eularis to Address Marketing Return at Pharmaceutical Marketing Society Half-day Conference: ROI or RIP?
4. MEDIA ALERT: Eularis to Address Marketing Return at Measuring Marketing ROI in Pharma Conference in London
5. Eularis Exposes Hidden Barriers to Patient Adherence With New Pharmaceutical Industry Report
6. Eularis to Address Making the Right Research Decision for ROI
7. Eularis Analyzes Most Effective Generics Defense Strategies With New Pharmaceutical Industry Report
8. MEDIA ALERT - Eularis to Hold Pharmaceutical Marketing ROI MasterClass in London
9. Cleveland Clinic Press Releases Journal-Writing Book Write for Life: Healing Body, Mind, and Spirit Through Journal Writing by Sheppard B. Kominars, Ph.D.
10. Leading Child Abuse Center Releases Back to School Tips to Protect Children From Internet Predators
11. JHA Releases 2007 U.S. Group Disability Mid-Year Market Survey Results
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/12/2017)... ... October 12, 2017 , ... Information about the ... to develop to enable prevention of a major side effect of chemotherapy in ... in pediatric patients. For cisplatin, hearing loss is FDA listed on-label as a ...
(Date:10/12/2017)... ... October 12, 2017 , ... HMP , a ... of a 2017 Folio Magazine Eddie Digital Award for ‘Best B-to-B Healthcare Website.’ Winners ... October 11, 2017. , The annual award competition recognizes editorial and design excellence across ...
(Date:10/12/2017)... Wesley Chapel, FL (PRWEB) , ... October 12, 2017 , ... ... Chapel is holding a treadmill relay – Miles by Moonlight to raise money for ... by donating $300 or more. , Teams will work together to keep their ...
(Date:10/12/2017)... ... October 12, 2017 , ... ... first interactive health literacy software tool, and the Cancer Patient Education Network (CPEN), ... patient education, today announce a new strategic alliance. , As CPEN’s strategic ...
(Date:10/12/2017)... ... 12, 2017 , ... Vohra Chief Medical Officer Dr. Shark ... skilled nursing facility medical directors and other clinicians at various events in October. ... "At many of these conferences we get to educate other physicians, facility nurses, ...
Breaking Medicine News(10 mins):
(Date:9/25/2017)... 25, 2017   Montrium , an industry ... today—from the IQPC Trial Master Files & Inspection ... that EastHORN Clinical Services has selected eTMF ... TMF management. EastHORN, a leading European contract research ... increase transparency to enable greater collaboration with sponsors, ...
(Date:9/23/2017)... -- Janssen Biotech, Inc. (Janssen) announced today that it ... Food and Drug Administration (FDA) for the Biologics License ... of moderately to severely active rheumatoid arthritis (RA). The ... to further evaluate the safety of sirukumab in the ... "We are disappointed by ...
(Date:9/22/2017)... , Sept. 22, 2017 AVACEN Medical ... device is now successfully helping those with the widespread ... Fibromyalgia diagnosed Amanda in Essex, England ... and washing my hair, experiencing no sleep at all, ... painful spasm… I cannot recommend [the AVACEN 100] enough, ...
Breaking Medicine Technology: